Advertisement

Rivastigmin

  • A. Enz
  • M. Rösler
Chapter

Zusammenfassung

Die Alzheimer’sche Krankheit (AD), zuerst beschrieben 1907 durch Alois Alzheimer, ist eine neurodegenerative Erkrankung, deren Ursache noch unbekannt ist und für die bis heute keine kausale Therapie existiert. Postmortale und moderne nicht-invasive bildgebende Verfahren liefern Hinweise, daβ im Gehirn von Alzheimer Patienten die Funktion vieler Neurotransmittersysteme durch die Krankheit gestört ist, wobei das cholinerge System besonders stark betroffen ist. Der Verlust cholinerger Neurone tritt auch frühzeitiger auf als derjenige anderer Transmittersysteme. Aus postmortem Untersuchungen an AD-Gehirnen wissen wir, daβ die Verminderung der Aktivität der Cholinacetyltransferase (ChAT), das für die Synthese von Acetylcholin (ACh) verantwortliche Enzym, mit dem Ausmaβ der kognitiven Störungen dieser Patienten korreliert. Diese Befunde sind die Basis der „Cholinergen Hypothese“, auf Grund derer verschiedene therapeutische Ansätze versucht wurden, nämlich die verminderte cholinerge Aktivität zu stimulieren und/oder zu erhalten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Enz A, Floersheim P (1996) Cholinesterase inhibitors: an overview of their mechanisms of action. In: Giacobini E, Becker R (eds) Alzheimer’s disease: from molecular biology to therapy. Birkhäuser, Boston, pp 211–215Google Scholar
  2. Enz A, Hofmann A, Gmelin G, Kelly PH (1989) Pharmacological properties of the preferentially centrally acting acetylcholinesterase inhibitor SD2 ENA 713. In: Kewitz H, Thomsen T, Bickel U (eds) Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). Zuckschwerdt, München, pp 271–277Google Scholar
  3. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowsky J (1993) Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. In: Cuello AC (ed) Colinergic function and dysfunction. Elsevier, Amsterdam, pp 431–438 (Prog Brain Res 98)CrossRefGoogle Scholar
  4. Karczmar A (1978) Exploitable aspects of cholinergic functions, particularly with respect to the EEG, motor, analgesic and mental functions. In: Jenden D, Hanin I (eds) Cholinergic mechanism and psychopharmacology. Plenum Press, New York, pp 679–708CrossRefGoogle Scholar
  5. Massoulie J, Pezzementi L, Bon S, Krejci E, Vallette FR (1993) Molecular and cellular biology of cholinesterases. Prog Neurobiol 41: 31–91 The molecular forms of Cholinesterase and acetylcholinesterase in vertebrates. Ann Rev Neurosci 5: 57–106PubMedCrossRefGoogle Scholar
  6. Niigawa H, Tanimukai S, Takeda M, Hariguchi S, Nishimura T (1995) Effects of SDZ ENA 713, a novel acetylcholinesterase inhibitor, on learning of rats with basal forebrain lesions. Prog Neuropsychopharmacol 19: 171–186CrossRefGoogle Scholar
  7. Ohara T, Tanaka K, Fukaya H, Demura N, Iimura A, Seno N (1997) SDZ ENA 713 facilitates central cholinergic functions and ameliorates spatial memory impairment in rats. Behav Brain Res 83: 229–233PubMedCrossRefGoogle Scholar
  8. Siek GC, Katz LS, Fishman EB, Korosi TS, Marquis JK (1990) Molecular forms of acetylcholinesterase in subcortical areas of normal and demented (Alzheimer-typ) patients. Biol Psychiatry 27: 573–580PubMedCrossRefGoogle Scholar
  9. Sussmann JL, Harel M, Frowlow F, Oefner C, Toker L, Silman I (1991) Atomic structure of aceylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253: 872–879CrossRefGoogle Scholar
  10. Tanaka K, Ogawa N, Asanuma M, Kondo Y, Mori A (1994) Chronic administration of acetylcholinesterase inhibitor in the senescent rat brain. Neurobiol Aging 15: 721–725PubMedCrossRefGoogle Scholar
  11. Whitehouse PJ (1993) Cholinergic therapy in dementia. Acta Neurol Scand [Suppl] 149: 42–45Google Scholar

Literatur

  1. Anand R, Gharabawi G (1996) Clinical development of Exelon® (Ena 713): the Adena programme. J Drug Dev Clin Pract 8: 9–14Google Scholar
  2. Anand R, Gharabawi G, Enz A (1996) Efficacy and safety results of the early phase studies with Exelon® (ENA 713) in Alzheimer’s disease: an overview. J Drug Dev Clin Pract 8: 1–8Google Scholar
  3. Corey-Bloom J, Anand R, Veach J (1998) A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65Google Scholar
  4. DeJong R, Osterlund O, Roy G (1989) Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 11: 545–554PubMedGoogle Scholar
  5. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J (1993) Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Prog Brain Res 98: 431–438PubMedCrossRefGoogle Scholar
  6. Rosen W, Mohs R, Davis K (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141: 1356–1364PubMedGoogle Scholar
  7. Rösler M, Anand R, Cicin-Sain A et al. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Br Med J 318: 633–638CrossRefGoogle Scholar
  8. Weinstock M, Razin M, Chorev M, Enz A (1994) Pharmacological evaluation of phenylcarbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm [Suppl] 43: 219–225Google Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • A. Enz
  • M. Rösler

There are no affiliations available

Personalised recommendations